DDInter1640 DDInter1676
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351]
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Saquinavir {u} (Compound) resembles {v} (Compound) Lopinavir
Saquinavir {u} (Compound) resembles {v} (Compound) Nelfinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Saquinavir {u} (Compound) binds {v} (Gene) SLCO1B1
Saquinavir {u} (Compound) upregulates {v} (Gene) UBQLN2
Saquinavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Saquinavir {u} (Compound) downregulates {v} (Gene) COG2
Saquinavir {u} (Compound) causes {v} (Side Effect) Renal failure acute
Saquinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Saquinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Saquinavir (Compound) resembles Lopinavir (Compound)
Saquinavir (Compound) resembles Nelfinavir (Compound)
Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Saquinavir (Compound) binds SLCO1B1 (Gene)
Saquinavir (Compound) upregulates UBQLN2 (Gene)
Saquinavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Saquinavir (Compound) downregulates COG2 (Gene)
Saquinavir (Compound) causes Renal failure acute (Side Effect)
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin human